Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
3.950
+0.080 (2.07%)
Dec 3, 2024, 1:40 PM EST - Market open
Valneva SE Revenue
Valneva SE had revenue of 45.82M EUR in the quarter ending September 30, 2024, with 20.36% growth. This brings the company's revenue in the last twelve months to 158.54M, down -28.98% year-over-year. In the year 2023, Valneva SE had annual revenue of 153.71M, down -57.46%.
Revenue (ttm)
158.54M EUR
Revenue Growth
-28.98%
P/S Ratio
n/a
Revenue / Employee
234,519 EUR
Employees
676
Market Cap
304.16M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accolade | 441.03M |
| Kamada | 158.38M |
| Sanara MedTech | 78.06M |
| NeuroPace | 76.45M |
| iTeos Therapeutics | 35.00M |
| C4 Therapeutics | 33.67M |
| Artiva Biotherapeutics | 2.60M |
| Immutep | 2.56M |
VALN News
- 13 hours ago - Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 7 days ago - Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA - GlobeNewsWire
- 18 days ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 20 days ago - Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire
- 24 days ago - Valneva SE (VALN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 weeks ago - Valneva to Present on Chikungunya at Several Leading Scientific Conferences - GlobeNewsWire
- 6 weeks ago - Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V - GlobeNewsWire